Vaping vs. Cigarettes: What Research Actually Shows

Bottom line: Vaping is neither as dangerous as smoking nor as safe as vaping’s early proponents claimed. The research has refined over a decade from theoretical harm estimates to actual clinical outcome data — and the picture is more complicated than either side of the debate suggests. Here’s what the current evidence shows.

Why the Comparison Is Harder Than It Looks

Cigarette smoking has a 70-year research base. We know with precision what it does to the human body: increases lung cancer risk by 15–25x, causes COPD in approximately 25% of lifetime smokers, increases cardiovascular disease risk by 2–4x, and is causally linked to cancers of the mouth, throat, esophagus, stomach, pancreas, kidney, bladder, and cervix.

Vaping has a 15-year research base, most of which is from products that no longer represent current devices. The studies that showed acute lung inflammation in 2015 were conducted on devices that ran at much lower temperatures and voltages than current high-output pod systems. This means existing research may underestimate exposure from modern products.

The population research is also complicated by the fact that most vaping studies compare three groups: people who only vape, people who only smoke, and dual users (who do both). The “vaping only” group is small — most adult vapers either switched from cigarettes (meaning they have prior cigarette exposure) or are dual users. Isolating the effects of vaping alone is methodologically difficult.

What the Comparison Actually Shows

The combustion advantage is real. The primary established benefit of vaping over cigarettes is the elimination of combustion. Cigarette smoke contains approximately 7,000 chemicals, including 70 established carcinogens, generated by burning tobacco at temperatures above 600°C. Vape aerosol is generated at 150–350°C — well below combustion temperature. The polycyclic aromatic hydrocarbons (PAHs) that are cigarette smoke’s primary carcinogens are either absent or present at dramatically lower levels in vape aerosol.

A 2021 Tobacco Control biomarker study compared smokers, vapers, and dual users. Exclusive vapers showed dramatically lower urinary levels of 1-OHP (a PAH biomarker linked to lung cancer) and NNAL (a tobacco-specific nitrosamine carcinogen) compared to smokers — roughly 95% lower and 90% lower respectively. This is the biological basis for the harm-reduction argument.

But vaping introduces its own toxicant exposures. The same 2021 study found that exclusive vapers had higher levels of certain metal biomarkers (nickel, chromium) compared to nonsmokers, likely from metal coil degradation in vaping devices. Formaldehyde and acrolein (a respiratory irritant) were detected in vape aerosol at levels above ambient air, though far below cigarette smoke levels.

A 2024 American Journal of Respiratory and Critical Care Medicine study of airway biopsies compared never-smokers, long-term vapers (5+ years), and long-term smokers. Findings: vapers showed intermediate levels of airway inflammation between never-smokers and smokers, with elevated inflammatory markers not seen in never-smokers but substantially lower than in smokers.

Cardiovascular effects persist. Nicotine itself — the compound present in both cigarettes and most vapes — causes vasoconstriction, increases heart rate and blood pressure, and promotes platelet aggregation. These cardiovascular effects are not eliminated by switching from cigarettes to vapes. A 2023 Journal of the American College of Cardiology meta-analysis found vapers had similar short-term cardiovascular endpoints to smokers, though long-term outcome data is not yet available.

The EVALI Outbreak: What It Revealed

The 2019–2020 EVALI outbreak was a significant inflection point in understanding vaping risk. Before 2019, the conventional wisdom was that vaping-related lung injury was theoretical. The outbreak demonstrated it was real and serious.

2,807 hospitalized cases and 68 deaths were linked primarily to vitamin E acetate — a thickening agent added to illicit THC cartridges, not standard nicotine vapes. The CDC investigation found 82% of EVALI cases involved THC-containing products, with vitamin E acetate detected in 94% of lung fluid samples from EVALI patients.

This matters for the risk assessment in two ways:

What EVALI confirmed: Vaping-induced acute lung injury is possible. The lung’s response to inhaled aerosol, even without combustion, can produce severe inflammation.

What EVALI doesn’t confirm: The main nicotine vaping products marketed by major manufacturers (Juul, Vuse, Lost Mary) do not typically contain vitamin E acetate. The EVALI-risk profile is concentrated in illicit THC cartridges from unregulated sources — a different product category.

The lesson for nicotine vapers is not that their products cause EVALI, but that the lung is not a neutral recipient of aerosol. Any inhaled substance carries some level of risk.

What the Research Says About Youth Vaping

The pediatric and adolescent vaping research is unambiguous: for people who have never smoked cigarettes, vaping is not a harm-reduction strategy — it is a harm-introduction strategy.

• Nicotine exposure during adolescent brain development. The developing brain continues forming until approximately age 25. Nicotine exposure during this period affects dopamine systems, impulse control circuits, and attention systems. The 2023 Surgeon General advisory on youth vaping cited fMRI studies showing structural differences in the prefrontal cortex of adolescent nicotine users compared to unexposed adolescents.

• Gateway to cigarettes. A 2022 JAMA Pediatrics meta-analysis of 16 longitudinal studies found that adolescent e-cigarette users were 3.1x more likely to take up cigarettes within 2 years than non-users — not less likely, which the harm-reduction argument would predict.

• High addiction rates. The 2023 National Youth Tobacco Survey found 63% of youth vapers had tried to quit in the past year and failed. The addiction rate in this population — many of whom have never smoked a cigarette — undermines the “gateway away from cigarettes” framing that early vaping proponents used.

What This Means for People Who Vape

For adult smokers who have switched completely to vaping: the harm-reduction evidence suggests vaping is a net benefit over continued cigarette smoking, primarily by eliminating combustion carcinogens. The American Cancer Society’s 2022 position statement acknowledges this while noting that complete cessation of all nicotine remains the optimal outcome.

For people who vape but have never smoked cigarettes: there is no established health benefit, and the evidence increasingly shows real harms — airway inflammation, nicotine dependence, and long-term risks that will become clearer as longitudinal data accumulates.

For people who dual-use (both vape and smoke): the harm-reduction benefit largely disappears. A 2023 Nicotine & Tobacco Research study found that dual users had similar biomarker levels to smokers, not to exclusive vapers. The lungs are not protected by partial substitution.

Quitting Both Is the Optimal Outcome

The research across cessation studies is consistent: the optimal health outcome from either vaping or smoking is complete cessation of all nicotine, not substitution of one delivery mechanism for another.

FDA-approved NRT products are the best-evidenced tool for achieving this. The 2022 Cochrane meta-analysis of 117 RCTs found that NRT (patches, gum, lozenges, inhaler, nasal spray) increases quit rates 50–60% versus placebo. Modern NRT designed for vapers — including nicotine mints that match the behavioral pattern of pod vaping — represents the current evidence-based approach.

The argument that “vaping helps people quit cigarettes” is partially supported by evidence. A 2019 NEJM RCT found e-cigarettes outperformed traditional NRT for cigarette cessation at 1 year (18% vs. 9.9%). But 80% of the e-cigarette group was still vaping at 1 year — meaning the “quit smoking” came with a new nicotine dependence, not true cessation. For people using vaping to quit cigarettes, the evidence-based endpoint is using the vape as a step toward eventual cessation of all nicotine, not as a permanent substitute.

---

For a practical guide on quitting vaping with FDA-approved NRT, see How to Quit Vaping in 2026. For understanding the nicotine metabolism timeline and withdrawal window, see How Long Does Nicotine Stay in Your System.